EDSA (Edesa Biotech) EBIT: $-10.41 Mil (TTM As of Mar. 2026)


EDSA Edesa Biotech Inc EDSA
26 GF Score
Price $7.95
! 2 Warning Signs
View Full Analysis

What is Edesa Biotech EBIT?

Edesa Biotech EDSA +5.58% 26 EBIT is $-10.41 Mil as of Mar. 2026. GuruFocus rates EDSA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Edesa Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-4.23 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-10.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Edesa Biotech's annualized ROC % for the quarter that ended in Mar. 2026 was -854.75%. Edesa Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Edesa Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -13.79%.

Edesa Biotech  (NAS:EDSA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Edesa Biotech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-16.924 * ( 1 - 0% )/( (1.993 + 1.967)/ 2 )
=-16.924/1.98
=-854.75 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.71 - 0.756 - ( 12.052 - max(0, 0.756 - 12.717+12.052))
=1.993

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12.385 - 2.188 - ( 10.004 - max(0, 2.188 - 10.418+10.004))
=1.967

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Edesa Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-16.924/( ( (0 + max(-0.090999999999998, 0)) + (0 + max(-1.774, 0)) )/ 2 )
=-16.924/( ( 0 + 0 )/ 2 )
=-16.924/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.431 + 0 + 0.234) - (0.756 + 0 + 0)
=-0.090999999999998

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.216 + 0 + 0.198) - (2.188 + 0 + 0)
=-1.774

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Edesa Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-10.413/75.518
=-13.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech EBIT Related Terms

Edesa Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Edesa Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech EBIT Chart

Edesa Biotech Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.34 -17.59 -8.64 -6.32 -7.13

Edesa Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -1.72 -2.22 -2.24 -4.23

EDSA vs PMVP, IMA, ENTX: EBIT Comparison

For the Biotechnology subindustry, Edesa Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's EV-to-EBIT falls into.


EDSA
26GF Score
Edesa Biotech Inc EDSA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edesa Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-10.41 Mil mean?
Edesa Biotech (EDSA) has a EBIT of $-10.41 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edesa Biotech.
Is Edesa Biotech's EBIT too high?
Edesa Biotech's current EBIT is $-10.41 Mil. Overall, Edesa Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Edesa Biotech's EBIT compare to PMVP and IMA?
Edesa Biotech's EBIT of $-10.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edesa Biotech. Edesa Biotech's current EBIT is $-10.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edesa Biotech stock overvalued right now?
Edesa Biotech (EDSA) has a current EBIT of $-10.41 Mil. The current EBIT is $-10.41 Mil. Edesa Biotech's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Edesa Biotech (EDSA), the current EBIT is $-10.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edesa Biotech Business Description

Address 100 Spy Court, Markham, ON, CAN, L3R 5H6
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
26GF Score

Get the complete analysis for EDSA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.95
Price